Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) is one of 944 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Centessa Pharmaceuticals to related businesses based on the strength of its earnings, profitability, valuation, risk, analyst recommendations, institutional ownership and dividends.
This is a breakdown of current ratings for Centessa Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Centessa Pharmaceuticals Competitors||2668||12367||38489||607||2.68|
Centessa Pharmaceuticals presently has a consensus target price of $11.50, suggesting a potential upside of 130.46%. As a group, “Pharmaceutical preparations” companies have a potential upside of 116.54%. Given Centessa Pharmaceuticals’ higher possible upside, equities analysts clearly believe Centessa Pharmaceuticals is more favorable than its rivals.
Valuation and Earnings
This table compares Centessa Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Centessa Pharmaceuticals||N/A||-$381.90 million||-2.10|
|Centessa Pharmaceuticals Competitors||$1.85 billion||$250.12 million||-2.59|
Centessa Pharmaceuticals’ rivals have higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Centessa Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Centessa Pharmaceuticals Competitors||-3,133.64%||-1,452.67%||-9.14%|
Institutional and Insider Ownership
95.7% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 45.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 9.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Centessa Pharmaceuticals rivals beat Centessa Pharmaceuticals on 7 of the 12 factors compared.
Centessa Pharmaceuticals Company Profile (Get Rating)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Receive News & Ratings for Centessa Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.